Cause-of-death analysis in patients with cardiac resynchronization therapy 491 41. Molhoek SG, Bax JJ, Bleeker GB, Boersma E, van Erven L, Steendijk P et al. 55. Romeyer-Bouchard C, Da Costa A, Dauphinot V, Messier M, Bisch L, Samuel B Comparison of response to cardiac resynchronization therapy in patients with et al. Prevalence and risk factors related to infections of cardiac resynchroniza- sinus rhythm versus chronic atrial fibrillation. Am J Cardiol 2004;94:1506–9. tion therapy devices. Eur Heart J 2010;31:203–10. 56. Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H et al; 42. Palmisano P, Accogli M, Pisano EC, Zaccaria M, De Blasi S, Ponzetta MA et al. MADIT-CRT Executive Committee. Predictors of super-response to cardiac Reduced long-term overall mortality in heart failure patients with prolonged resynchronization therapy and associated improvement in clinical outcome: the QRS treated with CRT combined with ICD vs. heart failure patients with narrow MADIT-CRT study. J Am Coll Cardiol 2012;59:2366–73. QRS treated with ICD only. Europace 201618:1374–82. 57. Schaer BA, Osswald S, Di Valentino M, Soliman OI, Sticherling C, ten Cate FJ 43. Pappone C, Vicedomini G, Augello G, Mazzone P, Nardi S, Rosanio S. et al. Close connection between improvement in left ventricular function by car- Combining electrical therapies for advanced heart failure: the Milan experience diac resynchronization therapy and the incidence of arrhythmias in cardiac with biventricular pacing-defibrillation backup combination for primary preven- resynchronization therapy-defibrillator patients. Eur J Heart Fail tion of sudden cardiac death. Am J Cardiol 2003;91:74F–80F. 2010;12:1325–32. 44. Schuchert A, Muto C, Maounis T, Frank R, Boulogne E, Polauck A et al; 58. Thijssen J, Borleffs CJ, Delgado V, van Rees JB, Mooyaart EA, van Bommel RJ MASCOT study group. Lead complications, device infections, and clinical out- et al. Implantable cardioverter-defibrillator patients who are upgraded and re- comes in the first year after implantation of cardiac resynchronization therapy- spond to cardiac resynchronization therapy have less ventricular arrhythmias defibrillator and cardiac resynchronization therapy-pacemaker. Europace compared with nonresponders. J Am Coll Cardiol 2011;58:2282–9. 2013;15:71–6. 59. Zecchin M, Proclemer A, Magnani S, Vitali-Serdoz L, Facchin D, Muser D et al. 45. Summary C. Contak cd. https://www.bostonscientific.com/content/dam/Manuals/ Long-term outcome of “super-responder” patients to cardiac resynchronization us/current-rev-en/358487-006_US_S.pdf (1 February 2016, date last accessed). therapy. Europace 2014;16:363–71. 46. Theuns DA, Schaer BA, Soliman OI, Altmann D, Sticherling C, Geleijnse ML 60. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. The prognosis of implantable defibrillator patients treated with cardiac et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. resynchronization therapy: Comorbidity burden as predictor of mortality. The effect of cardiac resynchronization on morbidity and mortality in heart fail- Europace 2011;13:62–9. ure. N Engl J Med 2005;352:1539–49. 47. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B et al; 61. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F et al. Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the Investigators. Combined cardiac resynchronization and implantable cardioversion mode of death in stable patients with heart failure: analysis from the sudden car- defibrillation in advanced chronic heart failure:the MIRACLE ICD Trial. JAMA diac death in heart failure trial. Circulation 2009;120:2170–6. 2003;289:2685–94. 62. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H et al; MADIT-II 48. Ypenburg C, van Bommel RJ, Borleffs CJ, Bleeker GB, Boersma E, Schalij MJ et al. Investigators. Risk stratification for primary implantation of a cardioverter- Long-term prognosis after cardiac resynchronization therapy is related to the ex- defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol tent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol 2008;51:288–96. 2009;53:483–90. 63. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT et al. 49. Expanded Indications for Medtronic CRT-D Based on REVERSE & RAFT Studies, Outcomes of implantable cardioverter-defibrillator use in patients with 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting comorbidities:results from a combined analysis of 4 randomized clinical trials. Materials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystem JACC Heart Fail 2014;2:623–9. DevicesPanel/UCM282274.pdf (1 February 2016, date last accessed). 64. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S 50. Bortnik M, Degiovanni A, Dell’era G, Cavallino C, Occhetta E, Marino P. et al. Gender differences in clinical outcome and primary prevention defibrillator Prevalence of ventricular arrhythmias in patients with cardiac resynchronization benefit in patients with severe left ventricular dysfunction: a systematic review therapy without back-up ICD: a single-center experience. J Cardiovasc Med and meta-analysis. Heart Rhythm 2010;7:876–82. 2014;15:301–6. 65. Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S et al; Executive 51. Piepoli MF, Villani GQ, Corr a U, Aschieri D, Rusticali G. Time course of effects Committee of the Multicenter Automatic Defibrillator Implantation Trial II. of cardiac resynchronization therapy in chronic heart failure: benefits in patients Long-term benefit of primary prevention with an implantable cardioverter- with preserved exercise capacity. Pacing Clin Electrophysiol 2008;31:701–8. defibrillator: an extended 8-year follow-up study of the Multicenter Automatic 52. Schuchert A, Muto C, Maounis T, Frank R, Ella RO, Polauck A et al; MASCOT Defibrillator Implantation Trial II. Circulation 2010;122:1265–71. Study Group. Gender-related safety and efficacy of cardiac resynchronization 66. Provid^ encia R, Boveda S, Lambiase P, Defaye P, Algalarrondo V, Sadoul N et al. therapy. Clin Cardiol 2013;36:683–90. Prediction of nonarrhythmic mortality in primary prevention implantable 53. Provid^ encia R, Marijon E, Lambiase PD, Bouzeman A, Defaye P, Klug D et al. cardioverter-defibrillator patients with ischemic and nonischemic cardiomyop- Primary prevention implantable cardioverter defibrillator (ICD) therapy in athy. JACC Clin Electrophysiol 2015;1:29–37. women-data from a Multicenter French Registry. J Am Heart Assoc 2016;5. 67. Upadhyay GA, Singh JP. Cause of death and CRT device selection: striving for 54. Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass DA et al. certitude? Eur Heart J 2015;36:2777–9. Cost effectiveness of cardiac resynchronization therapy in the Comparison of 68. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al; DANISH Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. Investigators. Defibrillator implantation in patients with nonischemic systolic J Am Coll Cardiol 2005;46:2311–21. heart failure. N Engl J Med 2016;375:1221–30. Corrigendum doi:10.1093/europace/eux204 Online publish-ahead-of-print 18 July 2017 ....................................................................................................................................................... Corrigendum to: Burri H, et al. Left univentricular pacing for cardiac resynchronization therapy [Europace 2017;19:912–9] This review was prepared by a writing group that was invited on behalf of the European Heart Rhythm Association (EHRA) Education Committee. The Committee would like to acknowledge that the EHRA Scientific Documents Committee members have acted as formal reviewers for this document: Gregory Lip (Chair), Bulent Gorenek (Co-Chair), Christian Sticherling, Laurent Fauchier, Andreas Goette, Werner Jung, Marc A. Vos, Michele Brignole, Christian Elsner, Gheorghe-Andrei Dan, Francisco Marin, Giuseppe Boriani, Deirdre Lane, Carina Blomstrom Lundqvist, and Irina Savelieva Published on behalf of the European Society of Cardiology. All rights reserved.V The Author 2017. For permissions, please email: firstname.lastname@example.org. Downloaded from https://academic.oup.com/europace/article-abstract/20/3/491/3871447 by Ed 'DeepDyve' Gillespie user on 16 March 2018
Europace – Oxford University Press
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera